Model driven method for exploring individual and confounding effects in spontaneous adverse event reporting databases
CONCLUSION: The study underscored that MD-ROR holds promise as a method for investigating individual and confounding effects in SAER databases.PMID:38073472 | DOI:10.1080/14740338.2023.2293200 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 11, 2023 Category: Drugs & Pharmacology Authors: Bo Lv Yuedong Li Aiming Shi Jie Pan Source Type: research
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
CONCLUSIONS: Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.PMID:38062555 | DOI:10.1080/14740338.2023.2293208 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Nemanja Z Petrovi ć Ana V Pej čić Ivan R Milovanovi ć Source Type: research
A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hypercholesterolemic patients
CONCLUSION: The pooled analysis of the existing evidence shows that inclisiran showed reduced risk of MACE along with excellent efficacy in managing dyslipidemia.PMID:38063346 | DOI:10.1080/14740338.2023.2293201 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Siddhartha Dutta Rima Shah Shubha Singhal Surjit Singh Kiran Piparva Chandan Dev Singh Katoch Source Type: research
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis
CONCLUSIONS: This study highlights the effectiveness of pharmaceutical care consultations in preventing MEs and improving surgical outcomes.PMID:38063348 | DOI:10.1080/14740338.2023.2292710 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Daniel Gomez Costas Almudena Ribed S ánchez Alvaro Gimenez Manzorro Ignacio Garutti Martinez Francisco Javier Sanz Fernandez Beatriz Torroba Sanz Sergio Herrero Bermejo Ana Mar ía Herranz-Alonso Mar ía Sanjurjo Source Type: research
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Expert Opin Drug Saf. 2023 Dec 8. doi: 10.1080/14740338.2023.2293206. Online ahead of print.ABSTRACTINTRODUCTION: The drug classes of α1-adrenoceptor antagonists, 5α-reductase inhibitors, and phosphodiesterase type 5 inhibitors are guideline recommended treatments of lower urinary tract symptoms suggestive of benign prostatic hyperplasia; muscarinic receptor antagonists and β3-adrenoceptor agonists are also recommended if storage symptoms are insufficiently addressed with one of the other three drug classes.AREAS COVERED: We provide a narrative review (no formalized literature searches performed) of the tolerability of ...
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: A Elif M üderrisoglu Jean J M C H de la Rosette Martin C Michel Source Type: research
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
CONCLUSIONS: Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.PMID:38062555 | DOI:10.1080/14740338.2023.2293208 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Nemanja Z Petrovi ć Ana V Pej čić Ivan R Milovanovi ć Source Type: research
A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hypercholesterolemic patients
CONCLUSION: The pooled analysis of the existing evidence shows that inclisiran showed reduced risk of MACE along with excellent efficacy in managing dyslipidemia.PMID:38063346 | DOI:10.1080/14740338.2023.2293201 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Siddhartha Dutta Rima Shah Shubha Singhal Surjit Singh Kiran Piparva Chandan Dev Singh Katoch Source Type: research
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis
CONCLUSIONS: This study highlights the effectiveness of pharmaceutical care consultations in preventing MEs and improving surgical outcomes.PMID:38063348 | DOI:10.1080/14740338.2023.2292710 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Daniel Gomez Costas Almudena Ribed S ánchez Alvaro Gimenez Manzorro Ignacio Garutti Martinez Francisco Javier Sanz Fernandez Beatriz Torroba Sanz Sergio Herrero Bermejo Ana Mar ía Herranz-Alonso Mar ía Sanjurjo Source Type: research
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Expert Opin Drug Saf. 2023 Dec 8. doi: 10.1080/14740338.2023.2293206. Online ahead of print.ABSTRACTINTRODUCTION: The drug classes of α1-adrenoceptor antagonists, 5α-reductase inhibitors, and phosphodiesterase type 5 inhibitors are guideline recommended treatments of lower urinary tract symptoms suggestive of benign prostatic hyperplasia; muscarinic receptor antagonists and β3-adrenoceptor agonists are also recommended if storage symptoms are insufficiently addressed with one of the other three drug classes.AREAS COVERED: We provide a narrative review (no formalized literature searches performed) of the tolerability of ...
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: A Elif M üderrisoglu Jean J M C H de la Rosette Martin C Michel Source Type: research
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
CONCLUSIONS: Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.PMID:38062555 | DOI:10.1080/14740338.2023.2293208 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Nemanja Z Petrovi ć Ana V Pej čić Ivan R Milovanovi ć Source Type: research
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
Expert Opin Drug Saf. 2023 Dec 4. doi: 10.1080/14740338.2023.2291865. Online ahead of print.ABSTRACTINTRODUCTION: In patients with an acute coronary syndrome (ACS), the ischemic benefit of antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that a bleeding event has prognostic implications (i.e. mortality) similar to a recurrent ischemic event led to the development of treatment regimens aimed at balancing both ischemic and bleeding risks.AREAS COVERED: This review aims at describing definitions, incidence and prognosis related to bleeding events in ACS patients as well as bleeding-avoidanc...
Source: Expert Opinion on Drug Safety - December 4, 2023 Category: Drugs & Pharmacology Authors: Claudio Laudani Davide Capodanno Angiolillo Dominick Joseph Source Type: research
